Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 12/20 | 0.70 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.54 |
| ▸ | GNRHR | P30968 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | USP19 | O94966 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140689 | 0.89 | CASR (0.68) | CASRNR1I2GNRHRCNR1CNR2 | |
| SCHEMBL4145492 | 0.84 | CASR (0.51) | CASRNR1I2GNRHRCNR1CNR2 | |
| SCHEMBL4149446 | 0.82 | CASR (1.00) | CASRNR1I2 | |
| SCHEMBL4142886 | 0.80 | CASR (0.66) | CASRNR1I2GNRHRCNR1CNR2 | |
| SCHEMBL3414739 | 0.78 | CASR (0.90) | CASRNR1I2 | |
| SCHEMBL3419297 | 0.76 | CASR (0.85) | CASRNR1I2 | |
| SCHEMBL3418007 | 0.75 | CASR (0.84) | CASRNR1I2 | |
| SCHEMBL4136034 | 0.74 | CASR (0.85) | CASRNR1I2 | |
| SCHEMBL13851662 | 0.74 | CASR (0.59) | CASRNR1I2GNRHR | |
| SCHEMBL4144975 | 0.74 | CASR (0.72) | CASRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | claimed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | CASR 12/4885NR1I2 3373/4885GNRHR 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.